Journal of Neuroimmunology
Volume 227, Issue 1 , Pages 190-194 , 8 October 2010

Natalizumab treatment reduces endothelial activity in MS patients

Received 11 May 2010 ,Revised 5 July 2010 ,Accepted 19 July 2010.

References 

  1. Brosnan CF, Cannella B, Battistini L, Raine CS. Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology. 1995;45:S16–S21
  2. Calabresi PA, Pelfrey CM, Tranquill LR, Maloni H, McFarland HF. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology. 1997;49:1111–1116
  3. Calabresi PA, Tranquill LR, Dambrosia JM, Stone LA, Maloni H, Bash CN, et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. Ann. Neurol. 1997;41:669–674
  4. Calabresi PA, Prat A, Biernacki K, Rollins J, Antel JP. T lymphocytes conditioned with Interferon beta induce membrane and soluble VCAM on human brain endothelial cells. J. Neuroimmunol. 2001;115:161–167
  5. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 1995;37:424–435
  6. Deisenhammer F. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes. CNS Drugs. 2009;23:379–396
  7. Deisenhammer F, Mayringer I, Harvey J, Dilitz E, Gasse T, Stadlbauer D, et al. A comparative study of the relative bioavailability of different interferon beta preparations. Neurology. 2000;54:2055–2060
  8. Engelhardt B, Ransohoff RM. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 2005;26:485–495
  9. Garton KJ, Gough PJ, Philalay J, Wille PT, Blobel CP, Whitehead RH, et al. Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). J. Biol. Chem. 2003;278:37459–37464
  10. Giovannoni G, Lai M, Thorpe J, Kidd D, Chamoun V, Thompson AJ, et al. Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging. Neurology. 1997;48:1557–1565
  11. Gneiss C, Brugger M, Millonig A, Fogdell-Hahn A, Rudzki D, Hillert J, et al. Comparative study of four different assays for the detection of binding antibodies against interferon-beta. Mult. Scler. 2008;14:830–836
  12. Graber J, Zhan M, Ford D, Kursch F, Francis G, Bever C, et al. Interferon-beta-1a induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis. J. Neuroimmunol. 2005;161:169–176
  13. Hartung HP, Reiners K, Archelos JJ, Michels M, Seeldrayers P, Heidenreich F, et al. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann. Neurol. 1995;38:186–193
  14. Hummel V, Kallmann BA, Wagner S, Fuller T, Bayas A, Tonn JC, et al. Production of MMPs in human cerebral endothelial cells and their role in shedding adhesion molecules. J. Neuropathol. Exp. Neurol. 2001;60:320–327
  15. Hurwitz E, Stancovski I, Sela M, Yarden Y. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc. Natl. Acad. Sci. U.S.A. 1995;92:3353–3357
  16. Jensen J, Krakauer M, Sellebjerg F. Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b. Cytokine. 2005;29:24–30
  17. Kallmann BA, Hummel V, Lindenlaub T, Ruprecht K, Toyka KV, Rieckmann P. Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1. Brain. 2000;123(Pt 4):687–697
  18. Khademi M, Bornsen L, Rafatnia F, Andersson M, Brundin L, Piehl F, et al. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur. J. Neurol. 2009;16:528–536
  19. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N. Engl. J. Med. 2005;353:369–374
  20. Kraus J, Engelhardt B, Chatzimanolis N, Bauer R, Tofighi J, Kuehne BS, et al. Cell surface bound and soluble adhesion molecules in CSF and blood in multiple sclerosis: correlation with MRI-measures of subclinical disease severity and activity. J. Neuroimmunol. 2002;122:175–185
  21. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 2005;353:375–381
  22. Man S, Tucky B, Bagheri N, Li X, Kochar R, Ransohoff RM. alpha4 Integrin/FN-CS1 mediated leukocyte adhesion to brain microvascular endothelial cells under flow conditions. J. Neuroimmunol. 2009;210:92–99
  23. Matusevicius D, Kivisakk P, Navikas VV, Tian W, Soderstrom M, Fredrikson S, et al. Influence of IFN-beta1b (Betaferon) on cytokine mRNA profiles in blood mononuclear cells and plasma levels of soluble VCAM-1 in multiple sclerosis. Eur. J. Neurol. 1998;5:265–275
  24. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2003;348:15–23
  25. Myers TJ, Brennaman LH, Stevenson M, Higashiyama S, Russell WE, Lee DC, et al. Mitochondrial reactive oxygen species mediate GPCR-induced TACE/ADAM17-dependent transforming growth factor-alpha shedding. Mol. Biol. Cell. 2009;20:5236–5249
  26. Oppermann K, Pilz G, Wipfler P, Sulzer C, Afazel S, Haschke-Becher E, et al. Short-term decrease of soluble adhesion molecules during natalizumab treatment. Mult. Scler. 2009;15:133
  27. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2006;354:899–910
  28. Rieckmann P, Altenhofen B, Riegel A, Baudewig J, Felgenhauer K. Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis. Ann. Neurol. 1997;41:326–333
  29. Rowinsky EK. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu. Rev. Med. 2004;55:433–457
  30. Shao MX, Nadel JA. Neutrophil elastase induces MUC5AC mucin production in human airway epithelial cells via a cascade involving protein kinase C, reactive oxygen species, and TNF-alpha-converting enzyme. J. Immunol. 2005;175:4009–4016
  31. Singh RJ, Mason JC, Lidington EA, Edwards DR, Nuttall RK, Khokha R, et al. Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3. Cardiovasc. Res. 2005;67:39–49
  32. Sixt M, Bauer M, Lammermann T, Fassler R. Beta1 integrins: zip codes and signaling relay for blood cells. Curr. Opin. Cell Biol. 2006;18:482–490
  33. Stuve O, Marra CM, Jerome KR, Cook L, Cravens PD, Cepok S, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann. Neurol. 2006;59:743–747
  34. Stuve O, Marra CM, Jerome KR, Cook L, Cravens PD, Cepok S, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann. Neurol. 2006;59:743–747
  35. Van AG, Van RM, Sciot R, Dubois B, Vermeire S, Noman M, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 2005;353:362–368
  36. Woodside DG, Kram RM, Mitchell JS, Belsom T, Billard MJ, McIntyre BW, et al. Contrasting roles for domain 4 of VCAM-1 in the regulation of cell adhesion and soluble VCAM-1 binding to integrin alpha4beta1. J. Immunol. 2006;176:5041–5049
  37. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992;356:63–66
  38. Zhang Z, Oliver P, Lancaster JR, Schwarzenberger PO, Joshi MS, Cork J, et al. Reactive oxygen species mediate tumor necrosis factor alpha-converting, enzyme-dependent ectodomain shedding induced by phorbol myristate acetate. FASEB J. 2001;15:303–305

PII: S0165-5728(10)00303-6

doi: 10.1016/j.jneuroim.2010.07.012

Journal of Neuroimmunology
Volume 227, Issue 1 , Pages 190-194 , 8 October 2010

Article Tools

* Image Usage & Resolution